Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2017
According to the recently published report 'Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2017'; Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 26 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.
Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.
The report 'Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2017' outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer and Oropharyngeal Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope